KEY DETAILS
FDA ordered Empower Pharmacy to stop making compounded semaglutide and tirzepatide, cutting off a major source of lower-cost GLP-1 drugs.
FDA charged two men in an international scheme that sold fake Ozempic to patients in the US and abroad.
Health Canada recalled Apo-Semaglutide injection pens because the dose display is incorrect, risking wrong doses.
FDA is still deciding, after nine years, which bulk chemicals compounding pharmacies may legally use for GLP-1 drugs.
A phase 3 trial found retatrutide lowers weight and blood sugar in people with obesity and type 2 diabetes.
The FDA has ordered one of the largest compounded GLP-1 pharmacies to stop making its versions of semaglutide and tirzepatide. If you have relied on Empower Pharmacy for a lower-cost refill, that option is now closing. The order arrived alongside other federal action against counterfeit sellers, a Canadian recall over a dosing error, and new trial data on next-generation weight loss drugs. Together, these updates matter because they affect where you can safely and legally get a GLP-1 medication, and at what cost.
Empower Pharmacy was one of the largest telehealth-linked compounders producing versions of semaglutide and tirzepatide, and its scale made it a common entry point for patients priced out of branded GLP-1 drugs. The FDA's September 18 warning letter directs the company to stop producing these compounded versions, which removes a channel many patients used when insurance would not cover Ozempic, Wegovy, Mounjaro, or Zepbound. Patients who filled prescriptions through Empower should expect their pharmacy or telehealth provider to reach out about next steps, since existing prescriptions may no longer be fillable through that route. I would suggest contacting your prescriber soon if you depend on this supply, so you have time to identify alternatives before a refill is due.
The FDA also announced charges against two men accused of running a scheme that distributed fake Ozempic to patients in the United States and other countries. Counterfeit products can contain the wrong ingredients, the wrong dose, or no active medication at all, which makes them a safety risk distinct from the cost concerns surrounding compounded drugs. This case shows that counterfeit GLP-1 products are being sold through international distribution networks, not just through isolated local sellers. If you buy a GLP-1 medication from a source outside your regular pharmacy or clinic, it is reasonable to ask for proof that the product came from an authorized distributor.
Health Canada's recall affects Apo-Semaglutide injection pens whose dose display does not match the actual dose being delivered. That mismatch means a patient could inject more or less medication than intended without any way to notice the error from the pen itself. The recall applies in Canada, so patients in the United States are not directly affected, but it is a reminder that manufacturing errors in GLP-1 delivery devices are not limited to any one country or product. If you use an injection pen, checking for recall notices tied to your specific lot number may be worth doing periodically.
The FDA has kept open, for nine years, a docket deciding which bulk chemicals compounding pharmacies may legally use to prepare GLP-1 medications for individual patients. This list matters because compounding pharmacies can only use substances the FDA has approved for that purpose, and the agency's slow pace has left compounders operating in a gray area while demand for cheaper alternatives to branded drugs has grown. The Empower Pharmacy warning letter and this unresolved docket are related, since enforcement actions against individual compounders happen inside a system that still lacks clear rules. Patients considering a compounded GLP-1 drug may want to understand that the underlying legal framework is still unsettled, not just the status of any single pharmacy.
A phase 3 trial called TRIUMPH-2 tested retatrutide in adults who have both obesity and type 2 diabetes, and the results showed reductions in both body weight and blood sugar. Retatrutide works on three hormone receptors rather than the one or two targeted by current GLP-1 drugs, which is part of why researchers are watching it closely as a possible next step in treatment. A separate trial of the same drug also reported improvement in sleep apnea and knee pain among people with obesity. These results support, though do not guarantee, a path toward FDA approval, and patients interested in newer options may want to ask their prescriber how clinical trial timelines affect when a drug like this could become available.
If you currently get semaglutide or tirzepatide through a compounding pharmacy, the most useful step is to confirm directly with your pharmacy whether your specific product is affected by the Empower order, since not every compounder is covered by this action. It is also worth asking your prescriber about FDA-approved alternatives and how their cost compares once compounded options narrow. Beyond your own prescription, keeping an eye on where a GLP-1 product came from, and confirming it was dispensed by a licensed pharmacy, remains a reasonable precaution given the counterfeit charges described above. None of this requires an immediate decision, but it does call for a conversation with whoever manages your prescription before your next refill is due.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.